Reviewing DBV Technologies (NASDAQ:DBVT) & Silexion Therapeutics (NASDAQ:SLXN)

DBV Technologies (NASDAQ:DBVT) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Profitability

This table compares DBV Technologies and Silexion Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-815.73%	-106.07%	-76.17%
Silexion Therapeutics	N/A	N/A	-249.43%

Risk and Volatility

DBV Technologies has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Silexion Therapeutics has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.

Insider & Institutional Ownership

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 10.9% of Silexion Therapeutics shares are held by institutional investors. 1.9% of DBV Technologies shares are held by company insiders. Comparatively, 33.0% of Silexion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for DBV Technologies and Silexion Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	0	0	2	0	3.00
Silexion Therapeutics	0	0	1	0	3.00

DBV Technologies currently has a consensus price target of $22.50, suggesting a potential upside of 426.07%. Silexion Therapeutics has a consensus price target of $9.00, suggesting a potential upside of 576.69%. Given Silexion Therapeutics’ higher probable upside, analysts plainly believe Silexion Therapeutics is more favorable than DBV Technologies.

Valuation and Earnings

This table compares DBV Technologies and Silexion Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$15.73 million	5.59	-$72.73 million	($4.50)	-0.95
Silexion Therapeutics	N/A	N/A	$260,000.00	N/A	N/A

Silexion Therapeutics has lower revenue, but higher earnings than DBV Technologies.

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.